HACKENSACK UNIVERSITY MEDICAL CENTER
1. Target Overview & Investment Thesis
HACKENSACK UNIVERSITY MEDICAL CENTER is a 779-bed large academic medical center in BERGEN, NJ with $2.00B in net patient revenue and a -2.5% operating margin. The hospital serves a payer mix of 26.0% Medicare, 4.8% Medicaid, and 69.1% commercial.
Thesis: Undervalued. Our ML models identify $146.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -2.5% to 4.8% (+736bps).
| Net Revenue HCRIS | $2.00B |
| Current EBITDA COMPUTED | $-50.2M |
| Operating Margin COMPUTED | -2.5% |
| Occupancy HCRIS | 78.9% |
| Revenue / Bed COMPUTED | $2.6M |
| Net-to-Gross HCRIS | 29.8% |
| Distress Probability ML | 41.9% |
2. Market Context & Competitive Position
NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of -2.5% places it above the state median. Among 15 size-comparable peers (390-1558 beds), the median margin is -4.3%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (390-1558), prioritizing same-state peers. 15 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| HACKENSACK UNIVERSITY MEDICAL (Target) | NJ | 779 | $2.00B | -2.5% |
| MORRISTOWN MEDICAL CENTER | NJ | 705 | $1.70B | 10.3% |
| COOPER UNIVERSITY HOSPITAL | NJ | 580 | $1.43B | 2.0% |
| ROBERT WOOD JOHNSON UNIVERSITY | NJ | 639 | $1.41B | -4.0% |
| JERSEY SHORE UNIVERSITY MED CT | NJ | 604 | $1.17B | 8.4% |
| COOPERMAN BARNABAS MEDICAL CEN | NJ | 554 | $1.07B | -4.3% |
| WEST JERSEY HEALTH SYSTEM | NJ | 587 | $958.4M | 7.1% |
| OVERLOOK MEDICAL CENTER | NJ | 440 | $880.2M | 8.9% |
| ST. JOSEPHS UNIVERSITY MEDICAL | NJ | 692 | $801.6M | -14.6% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $146.9M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $41.9M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $39.9M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $39.5M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $24.3M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $1.3M | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-50.2M |
| + RCM Uplift | +$146.9M |
| Pro Forma EBITDA | $96.7M |
| Current Margin | -2.5% |
| Pro Forma Margin | 4.8% |
| WC Released (1x) | $76.6M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-77.3M | $1.14B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-77.3M | $1.23B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-69.6M | $1.69B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-69.6M | $1.82B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-85.0M | $428.4M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-85.0M | $443.6M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 15 hospitals with 390-1558 beds
- Same-state prioritization (n=16)
- Comp margins: P25=-11.8% / P50=-4.3% / P75=4.7%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.